Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,821 JPY | +1.75% | +3.54% | +3.26% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The stock, which is currently worth 2024 to 0.16 times its sales, is clearly overvalued in comparison with peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Sales forecast by analysts have been recently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.26% | 2.45B | C+ | ||
-1.88% | 24.09B | C+ | ||
+7.11% | 8.2B | B | ||
-20.55% | 7.97B | B- | ||
-4.06% | 7.84B | C | ||
+2.26% | 4.66B | B- | ||
+17.12% | 4.32B | B+ | ||
+1.41% | 4.19B | B- | ||
-3.02% | 3.89B | B | ||
+21.42% | 3.62B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 9987 Stock
- Ratings Suzuken Co., Ltd.